Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
US rare disease specialist Insmed plans to double its Japan sales force to around 100 by 2026, as it readies for the commercial debut of its bronchiectasis drug brensocatib. The hiring drive — set to begin early next year —…
To read the full story
Related Article
- Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
- Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
- Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
- Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
BUSINESS
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…